BioNTech CEO Ugur Sahin Sells $7.19M in Ordinary Shares via Rule 10b5-1 Plan

Insider Transaction Summary

BioNTech SE Chief Executive Officer and 10% beneficial owner Ugur Sahin reported open-market sales of 73,000 Ordinary Shares over two consecutive trading sessions on September 8 and September 9, 2026, generating gross proceeds of approximately $7.19 million.

Key Transaction Details:

• September 8, 2026: Sold 37,000 shares at a weighted-average price of $99.2032 per share.
• September 9, 2026: Sold 36,000 shares at a weighted-average price of $97.7818 per share.
• Aggregate Proceeds: $7,190,663.20
• Trading Plan: Sales were executed under a pre-established Rule 10b5-1 trading plan adopted on June 3, 2026.

Post-Transaction Ownership:

• Direct Ownership: 708,709 shares following the transactions.
• Indirect Ownership: 39,218,111 shares held through Medine GmbH, of which Dr. Sahin is the sole shareholder.

Significance:

The sale represents less than 0.2% of Dr. Sahin's total combined direct and indirect beneficial ownership (~39.9 million shares) and was conducted via a pre-scheduled Rule 10b5-1 plan, indicating routine liquidity management rather than a directional signal on the company's outlook.